Pharmaceutical Executive January 13, 2026
Key Takeaways
- Bayer’s transformation focuses on a revitalized portfolio, strong pipeline, and strategic operational changes for sustained growth.
- New product launches generated $1.7 billion in revenue, highlighting the success of Bayer’s portfolio refresh and business resilience.
- Key growth catalysts include Nubeqa, Kerendia, Lynkuet, Asundexian, and U.S. cardiovascular market reentry.
- Operational efficiency, innovation, and strategic partnerships are central to Bayer’s strategy, aiming for mid-single-digit revenue growth and margin expansion.
Bayer’s strategic portfolio refresh, late-stage pipeline progress, and operational efficiency positions the company for long-term growth across cardiovascular, oncology, and women’s health.
The second day at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 13, saw Bayer CEO Stefan Orick detail the company’s transformation following...
Today's Sponsors
Today's Sponsor